Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05912387 |
Recruitment Status :
Recruiting
First Posted : June 22, 2023
Last Update Posted : March 21, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Sclerosing Cholangitis Inflammatory Bowel Diseases | Drug: Rosuvastatin | Early Phase 1 |
Database studies have suggested that use of statins is associated with lower mortality in patients with PSC. Statins are also safe, widely used medications for the treatment of high cholesterol. This track record of safety makes repurposing statins for use in PSC an attractive option.
This study will evaluate the impact of bile acid profile and the microbiome. Rosuvastatin induced changes in cell signaling pathways in the body, as well as its impact of bacterial gene expression in the microbiome will be evaluated. The investigators anticipate that this study will provide key insights into the biologic basis of PSC, which may aid in the development of drugs for the treatment of PSC.
This research study will enroll patients with PSC. The study will be conducted in 3 phases: baseline measurements, study period (treatment with rosuvastatin), and follow-up (follow-up after completing statin treatment). All patients will receive the study drug, and no patients will receive placebo treatment. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | The Effect of Statin Therapy on Bile Acid Physiology and the Microbiome in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study |
Actual Study Start Date : | May 31, 2023 |
Estimated Primary Completion Date : | May 31, 2025 |
Estimated Study Completion Date : | December 31, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Rosuvastatin therapy
Participants will receive rosuvastatin for 12 weeks followed by a 2 week washout period prior to the final follow-up visit. All patients will receive the study drug, and will serve as their own control. No participants will receive placebo. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.
|
Drug: Rosuvastatin
Rosuvastatin 20 mg tablet once daily by mouth |
- Change in bile acid (BA) profile: total bile acid [ Time Frame: Baseline and week 12 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in bile acid (BA) profile: secondary bile acids:primary bile acids ratio [ Time Frame: Baseline and week 12 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in bile acid (BA) profile: conjugated:unconjugated BAs ratio [ Time Frame: Baseline and week 12 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in pathogen density in the small intestine [ Time Frame: Baseline and week 12 ]Measure impact of statin therapy upon pathogen density (ratio of good bacteria to pathogenic bacteria) within the microbial community of the duodenum.
- Change in bacterial gene expression profile in the small intestine [ Time Frame: Baseline and week 12 ]This outcome aims to develop an understanding of the profile of microbial metabolic pathways in the duodenum and changes to the profile in response to statin therapy; gene sequencing with be done using shotgun metagenomics followed by pathway analysis.
- Change in bile acid (BA) profile: total bile acid [ Time Frame: Baseline, week 4, week 14 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in bile acid (BA) profile: secondary bile acids:primary bile acids ratio [ Time Frame: Baseline, week 4, week 14 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in bile acid (BA) profile: conjugated:unconjugated BAs ratio [ Time Frame: Baseline, week 4, week 14 ]BA profile of biliary/intestinal aspirate and/or feces in response to statin therapy.
- Change in pathogen density in the small intestine [ Time Frame: Baseline, week 4, week 14 ]Measure impact of statin therapy upon pathogen density (ratio of good bacteria to pathogenic bacteria) within the microbial community of the duodenum.
- Change in bacterial gene expression profile in the small intestine [ Time Frame: Baseline, week 4, week 14 ]This outcome aims to develop an understanding of the profile of microbial metabolic pathways in the duodenum and changes to the profile in response to statin therapy; gene sequencing with be done using shotgun metagenomics followed by pathway analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males and females, greater than or equal to 18 years of age
- Established diagnosis of PSC, defined by either appropriate cholangiographic findings or supportive liver biopsy plus an established diagnosis of inflammatory bowel disease (IBD - Crohn's disease or ulcerative colitis) per American College of Gastroenterology (ACG) guidelines for the PSC-IBD arm
- Hypercholesterolemia with BMI < 25.0 for the comparison arm
Exclusion Criteria:
- Diagnosis of PSC-autoimmune hepatitis overlap syndrome
- Woman who are pregnant, nursing, or expect to be pregnant
- The presence of any comorbidity known to cause secondary sclerosing cholangitis, including: immunoglobulin G-4 (IgG4), associated cholangitis, recurrent bacterial cholangitis, recurrent pyogenic cholangitis, ischemic cholangiopathy, surgical biliary trauma, cholangiocarcinoma, and portal hypertensive biliopathy
- Diagnosis of a serious medical condition (unless approved in writing by a physician)
- Patients taking statin therapy prior to study initiation
- Patients with known clinically allergy to statin therapy
- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5 times the upper limit of normal
- Bilirubin greater than 3.0 mg/dL
- Recent use of antibiotics (within the last 90 days)
- Concurrent use of any immunosuppressive medications (such as any calcineurin inhibitor, steroids at a dose greater than 10 mg of prednisone-equivalents per day)
- Actively using a fibrate drug
- Actively using a ritonavir containing drug
- Familial hypercholesterolemia or other inherited disorder of lipid metabolism
- Recent myocardial infarction or cerebrovascular accident
- Body mass index > 25.0 for the comparison arm
- Chronic kidney disease stage 5 or end-stage renal disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05912387
Contact: Touran Fardeen | (650) 725-5890 | tfardeen@stanford.edu |
United States, California | |
Stanford University | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Touran Fardeen tfardeen@stanford.edu |
Principal Investigator: | Sidhartha Sinha, MD | Stanford University |
Responsible Party: | Sidhartha Ranjit Sinha, Principal Investigator, Stanford University |
ClinicalTrials.gov Identifier: | NCT05912387 |
Other Study ID Numbers: |
67292 |
First Posted: | June 22, 2023 Key Record Dates |
Last Update Posted: | March 21, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual participant data will not be shared |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Statin |
Inflammatory Bowel Diseases Cholangitis Cholangitis, Sclerosing Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Bile Duct Diseases Biliary Tract Diseases |
Rosuvastatin Calcium Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |